MTOR and acute myeloid leukemia: Tan et al. evaluated the maximum tolerated dose (MTD) and efficacy of everolimus, a more potent mTOR inhibitor than sirolimus, in combination with azacitidine subcutaneously in an open-label, Phase 1b/2 study in relapsed/refractory AML.